drugset / Trial / NCT02175017
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of the study is to investigate the efficacy and safety of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.
Timeline
- Start
- 2014-06
- Primary completion
- 2015-11
- Completion
- 2021-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |